Amgen and AstraZeneca’s inflammatory disease drug Tezspire has clinched
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock…
Antibody-drug conjugates from Kelun-Biotech and Hansoh Pharma, respectively partnered with Merck & Co. and GSK, delivered…
Astellas CEO explained to Fierce the company's new five-year plan. A Takeda candidate beat Bristol Myers Squibb's Sotyktu in a…
AstraZeneca & Amgen’s Tezspire achieves significant Phase 3 CROSSING trial results in eosinophilic esophagitis (EoE) treatment.
Less than a month after an FDA advisory committee voted 6-3 | Less than a month after an FDA advisory committee recommended…
AstraZeneca has fired another volley in its bladder cancer competition with Merck’s Keytruda, with the FDA on Thursday
